Vir Biotechnology Inc. (NASDAQ: VIR) reported Q4 EPS of ($0.76), $0.41 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $49.4 million versus the consensus estimate of $149.6 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.